cancer cancer guidelines clinical trials cancer patients oncology cancer physicians cancer hospitals oncology
NCCN - National Comprehensive Cancer Network National Comprehensive Cancer Network Homepage Patients with Cancer Cancer Clinicians Cancer Industry About National Comprehensive Cancer Network

 

Contact Us / Privacy Policy

 

Download the PDF booklet

Order a printed copy of the booklet


Contents

 

Introduction

Detection

Stages

Treatment

Side Effects

Glossary

Help


Decision Trees

Work-Up (Evaluation)

Low Recurrence Risk

High Risk of Recurrence or Spread

Recurrence Follow-up

Return After Radical Prostatectomy

Return After Radiation Therapy

Systemic Treatment, Widespread

 

 

   
 

Prostate Cancer Stages

American Cancer Society


A prostate cancer’s stage indicates how far it has spread within the prostate, to nearby tissues, and to other organs. The stage of a cancer is one of the most important factors in selecting treatment options. It is also the most significant (but not the only) factor in predicting a man’s outlook for survival (prognosis).

A staging system is a standardized way in which the cancer care team describes the extent to which a cancer has spread. The most commonly used system in the United States is called the TNM System of the American Joint Committee on Cancer (AJCC). The TNM System describes the extent of the primary tumor (T), the absence or presence of spread to nearby lymph nodes (N), and the absence or presence of spread to distant organs (M).

The stages described here are based on the most recent version (2002) of the AJCC staging manual.

 

T Categories

There are actually two types of T classifications for prostate cancer.

  • The clinical stage is your doctor’s best estimate of the extent of the disease based on digital rectal exam (DRE), needle biopsy, and any imaging studies that were done.
  • The pathologic stage is based on surgical removal and examination of the entire prostate gland, both seminal vesicles (two small sacs next to the prostate that store semen) and, in some cases, nearby lymph nodes.

The clinical stage is used in making treatment decisions, such as whether a patient might benefit from treating the prostate cancer with surgery or radiation. However, the clinical stage may underestimate the extent of cancer spread, and if surgery is done, the pathologic stage assigned after surgery is more accurate. Men who do not have a radical prostatectomy (surgery to remove the prostate gland, seminal vesicles, and nearby tissues) do not have a pathologic T stage determined. There are 4 categories for describing the prostate cancer’s T stage.

  • T1 refers to a tumor that is not felt during a digital rectal exam, but cancer cells are found in a prostate biopsy or prostatectomy specimen (if prostatectomy has been performed for benign prostatic enlargement). T1 prostate cancers can be further subclassified as T1a, T1b, and T1c.
    • T1a describes prostate cancers found incidentally (by accident) during transurethral resection of the prostate (TURP) or open prostate removal (simple prostatectomy). These are surgical procedures done to relieve symptoms of benign prostate hypertrophy (prostate enlargement that is not caused by cancer). This operation is usually done because the enlarged prostate gland presses on the urethra and makes it difficult for a man to urinate. When prostate tissue is removed and checked under the microscope, cancer may be found, even though the doctor who removed the tissue did not expect cancer to be present. T1a indicates that less than 5% of the tissue removed is cancer and more than 95% is benign.
    • T1b also describes cancers found incidentally during TURP or simple prostatectomy, but more than 5% of the removed tissue is cancer.
    • T1c cancers are found by biopsy. In these cases a core needle biopsy is usually done because the PSA blood test result was elevated, suggesting that a cancer might be present.
  •  T2 means that a doctor can feel the prostate cancer by DRE and that the cancer is thought to remain within the prostate gland. This category is subclassified into T2a and T2b and T2c.
    • T2a means that the cancer is in only one side of the prostate, and is in only half (or less) of that side.
    • T2b cancers are in only one side of the prostate, but are in more than half of that side.
    • In T2c cancer, the cancer is in both sides of the prostate gland.
  • T3 cancers have spread beyond the outer rim (capsule) that surrounds the gland. They have reached the connective tissue next to the prostate and/or the seminal vesicles, but have not spread to any other organs. This group is divided into T3a and T3b.
    • In T3a, the cancer is growing outside the prostate but has not spread to the seminal vesicles.
    • A T3b cancer has spread to the seminal vesicles.
  • T4 means that the cancer has spread to tissues next to the prostate (other than the seminal vesicles), such as the bladder neck or its external sphincter (muscle that helps control urination), the rectum, the muscles in the pelvis, or the wall of the pelvis.

 

N Categories

The N category is determined by whether or not the cancer has been found in nearby lymph nodes.

  • NX means that tests to detect lymph node spread have not been done.
  • N0 means that the cancer has not spread to any lymph nodes.

  • N1 means spread to nearby lymph node in the pelvis

 

M Categories

The M category stands for metastasis, or whether or not the cancer has spread to distant organs.

  • MX means that tests to detect distant spread have not been done.
  • M0 means that the cancer has not spread beyond the nodes in the pelvis.
  • M1 means the cancer has spread to distant sites.

    • M1a means the cancer has spread to distant lymph nodes.
    • M1b means the cancer has spread to bone(s).
    • M1c means the cancer has spread to other organs such as lungs, liver, or brain.

Although in this AJCC staging system, the T, N, M stages are to be combined into a single Roman numeral I–IV, this is not often needed for prostate cancer because the stages follow the T stage. Stage I = T1, Stage II = T2, Stage III = T3, and Stage IV includes T4 and spread to lymph nodes or distant sites.

A special note about bone metastases

Most of the time even though the cancer has spread to the bone, the bone is not weakened. X-rays often show that the bone appears denser and even harder. These are called blastic metastases. Sometimes, the cancer will dissolve the bones and severely weaken them. These are called lytic metastases. Lytic metastases may be caused by the small cell or neuroendocrine type of prostate cancer.

 

Partin tables

These tables take the results of the PSA test, the clinical stage (T1 or T2), and the Gleason score and combine them to predict the chance that the cancer has spread outside the prostate, to the seminal vesicles, or to nearby lymph nodes. The tables are used to help estimate a patient’s risk of spread so that appropriate tests, such as CT scan or MRI, may be done. They also help doctors plan treatment. The tables have not been included in this booklet but can be found on the Web at http://urology.jhu.edu/Partin_tables/.

Some of the treatment options listed in the patient Decision Trees are based on the probability of cancer spread. These probabilities come from Partin Tables.

 

 

 EARLY DETECTION TYPES OF TREATMENT

 

For more information on these treatment guidelines, or on cancer in general, call the NCCN at 1-888-909-NCCN or the American Cancer Society at 1-800-ACS-2345. Or you can visit these organizations’ web sites at www.cancer.org (ACS) and www.nccn.org (NCCN).

 

© 2005 by the National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS). All rights reserved. The information herein may not be reproduced in any form for commercial purposes or downloaded and stored in any information-retrieval system without the express written permission of the NCCN and the ACS. Single copies of each page may be printed out for personal, noncommercial use only.

 

Educational Opportunities

NCCN 1st Annual Forum: Innovative Diagnostics & Therapeutics in Cancer Care™

September 4, 2008
New York Marriott at the Brooklyn Bridge
New York, New York

NCCN 3rd Annual Congress: Hematologic Malignancies™

September 5 – 6, 2008
New York Marriott at the Brooklyn Bridge
New York, New York


Exhibitor Information


NCCN Regional Guidelines Symposia

NCCN Non-Small Cell Lung Cancer Guidelines Symposium
Birmingham, Michigan (Friday, September 12, 2008)

NCCN Breast Cancer Guidelines Symposium
Durham, North Carolina (Monday, September 22, 2008)

NCCN Colon and Rectal Cancers Guidelines Symposia
New York , New York (Tuesday, September 23, 2008)

NCCN Head and Neck Cancers Guidelines Symposia
Omaha, Nebraska (Friday, October 10, 2008)

NCCN Breast Cancer Guidelines Symposium
Tampa, Florida (Monday, October 20, 2008)

NCCN Non-Small Cell Lung Cancer Guidelines Symposium
Durham, North Carolina (Monday, November 03, 2008)

More Events ....


NCCN International

Chinese – 中文

Japanese –日本語

NCCN Privacy Policy NCCN Legal Disclaimer NCCN Site Map Contact NCCN Home National Comprehensive Cancer Network